Logo

Pfizer Signs a Worldwide License Agreement with Theravance BioPharma for its Pan-JAK Inhibitor Program

Share this

Pfizer Signs a Worldwide License Agreement with Theravance BioPharma for its Pan-JAK Inhibitor Program

Shots:

  • Theravance to receive $10M up front- up to $240M development & commercial milestones with royalties on global sales of any product developed from the program. Pfizer to get a global license for Theravance’s skin-targeted- LA- pan-Janus kinase (JAK) inhibitors  
  • Pfizer will validate Theravance’s expertise in the discovery & development of organ-selective JAK inhibitors while the program will complement Pfizer’s portfolio of pre/ clinical-stage molecules targeting unmet medical needs
  • JAK inhibitors act by targeting the JAK enzyme- thus interfering with the JAK/STAT signaling pathway which resulted in modulating the activity of a wide range of pro-inflammatory cytokines. The compounds in the program are designed to possess skin-selective activity with minimal systemic exposure

Click here ­to­ read full press release/ article | Ref: Theravance | Image: Office Snapshot


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions